KAI-4729 An investigational once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist being developed for obesity treatment.
Visit productCosigns Received
Be the first Cosign
Put your name behind KAI-4729.
Add it to your Products I use list and share why you use it.